SCHEMBL815719

SCHEMBL815719

[CH2]c1cccc(CCCC)c1CCCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 1/20 0.39
ALOX5 P09917 1/20 0.39
PTGS2 P35354 1/20 0.39
BID P55957 3/20 0.37
MCL1 Q07820 3/20 0.37
BCL2L1 Q07817 2/20 0.37
BAK1 Q16611 2/20 0.37
KAT8 Q9H7Z6 2/20 0.37
PPARA Q07869 2/20 0.37
PPARG P37231 1/20 0.37
EP300 Q09472 1/20 0.37
KAT2A Q92830 1/20 0.37
KAT2B Q92831 1/20 0.37
KAT5 Q92993 1/20 0.37
SAE1 Q9UBE0 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
TYR P14679 1/20 0.36
CYSLTR2 Q9NS75 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL817803 0.92 LIPG (0.49) LIPGALOX5PTGS2BIDMCL1
SCHEMBL11333647 0.92 LIPG (0.49) LIPGALOX5PTGS2BIDMCL1
SCHEMBL10354084 0.92 LIPG (0.49) LIPGALOX5PTGS2BIDMCL1
SCHEMBL819273 0.85 LIPG (0.45) LIPGALOX5PTGS2BIDMCL1
SCHEMBL4857184 0.84 GABRA1 (0.40) LIPGALOX5PTGS2CYP3A4CYP2D6
SCHEMBL818006 0.83 KDM4E (0.35) ALOX5PTGS2HPGD
Ammonia Solution, Strong SCHEMBL9810933 0.83 LIPG (0.44) LIPGALOX5PTGS2BIDMCL1
Water SCHEMBL27341058 0.83 LIPG (0.44) LIPGALOX5PTGS2BIDMCL1
SCHEMBL816916 0.82 TYR (0.41) LIPGALOX5CYP3A4CYP2D6CYP2C9
SCHEMBL392416 0.81 LIPG (0.47) LIPGALOX5PTGS2BIDMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11248011-B2 Phosphorus-based releasing agent, optical polymerizable composition comprising same and preparation thereof SKC CO., LTD. (KR) 2022-02-15 US claimed
US-20190263846-A1 PHOSPHORUS-BASED RELEASING AGENT, OPTICAL POLYMERIZABLE COMPOSITION COMPRISING SAME AND PREPARATION THEREOF SK PUCORE CO., LTD. (KR) 2019-08-29 US claimed
EP-3530684-A1 PHOSPHORUS-BASED RELEASING AGENT, OPTICAL POLYMERIZABLE COMPOSITION COMPRISING SAME AND PREPARATION THEREOF SKC Co., Ltd. (KR) 2019-08-28 EP claimed
US-7247687-B2 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-07-24 US claimed
EP-1521758-B1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEM PATENTS INC (US) 2006-05-24 EP claimed
US-20060047094-A1 Late transition metal catalysts for olefin polymerization and oligomerization EXXONMOBIL CHEMICAL PATENTS INC. 2006-03-02 US claimed
EP-1521758-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION Exxonmobil Chemical Patents Inc. (US) 2005-04-13 EP claimed
WO-2004007509-A1 LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-01-22 WO claimed
US-11723888-B2 Polymer conjugated thyrointegrin antagonists NANOPHARMACEUTICALS LLC (US) 2023-08-15 US disclosed
US-20230181501-A1 POLYMER CONJUGATED THYROINTEGRIN ANTAGONISTS NANOPHARMACEUTICALS LLC 2023-06-15 US disclosed
WO-2023107412-A1 POLYMER CONJUGATED THYROINTEGRIN ANTAGONISTS NANOPHARMACEUTICALS LLC (US) 2023-06-15 WO disclosed
CN-110183603-B Phosphorus-containing release agent, optical polymerizable composition containing same, and method for producing same SKC株式会社 2023-04-07 CN disclosed
EP-4142798-A1 COMPOSITION OF SCALABLE THYROINTEGRIN ANTAGONISTS WITH IMPROVED BLOOD BRAIN BARRIER PENETRATION AND RETENTION IN BRAIN TUMORS NanoPharmaceuticals LLC (US) 2023-03-08 EP disclosed
US-11248011-B2 Phosphorus-based releasing agent, optical polymerizable composition comprising same and preparation thereof SKC CO., LTD. (KR) 2022-02-15 US disclosed
EP-0017623-A2 Hardenable mixtures containing dimethylamino derivatives CIBA-GEIGY AG (CH) 1980-10-15 EP disclosed
EP-0016722-A1 Stabilised flame-resistant plastics moulding composition and process for stabilising plastics made flame-resistant with organic bromine compounds CIBA-GEIGY AG (CH) 1980-10-01 EP disclosed
US-4133830-A RECYCLING BY-PRODUCTS TO SUCCESSIVE RUNS TO IMPROVE YIELD STAUFFER CHEMICAL COMPANY (US) 1979-01-09 US disclosed
US-4130583-A AUTOGENOUS PRESSURE STAUFFER CHEMICAL COMPANY (US) 1978-12-19 US disclosed
US-4112024-A PESTICIDES EXXON RESEARCH & ENGINEERING CO. (US) 1978-09-05 US disclosed
US-4003939-A PESTICIDES EXXON RESEARCH AND ENGINEERING COMPANY (US) 1977-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11723888-B2 Polymer conjugated thyrointegrin antagonists TEK, HDGF, PTGFR LIPG 666/4885ALOX5 2497/4885PTGS2 889/4885
US-20060047094-A1 Late transition metal catalysts for olefin polymerization and oligomerization MLX, LOX, LMTK3 LIPG 2752/4885ALOX5 188/4885PTGS2 3242/4885
US-20230181501-A1 POLYMER CONJUGATED THYROINTEGRIN ANTAGONISTS TEK, HDGF, PTGFR LIPG 666/4885ALOX5 2497/4885PTGS2 889/4885
US-20190263846-A1 PHOSPHORUS-BASED RELEASING AGENT, OPTICAL POLYMERIZABLE COMPOSITION COMPRISING SAME AND PREPARATION THEREOF PMM2, PGM2, IPMK LIPG 1449/4885ALOX5 539/4885PTGS2 3246/4885
US-11248011-B2 Phosphorus-based releasing agent, optical polymerizable composition comprising same and preparation thereof PMM2, PGM2, IPMK LIPG 1449/4885ALOX5 539/4885PTGS2 3246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.